Search Results

Corporate

September 13, 2017

Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies

Shark Tank’s Daymond John to Judge the First Champions of Science “What’s New?” Challenge Multifaceted Platform to Broaden Public Engagement in Science

Innovative Medicine

September 6, 2017

ACTELION RECEIVES FDA APPROVAL OF TRACLEER® (bosentan) FOR USE IN PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

--First PAH medication approved in the U.S. for pediatric patients aged three years and older--

Innovative Medicine

September 5, 2017

Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

Innovative Medicine

August 27, 2017

XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study

Innovative Medicine

August 21, 2017

New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study

Innovative Medicine

August 16, 2017

Johnson & Johnson Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments

Memorandum of Understanding brings together best scientists from India and Johnson & Johnson to increase and accelerate pace of innovation needed to make TB history

Innovative Medicine

August 2, 2017